Caricamento...
Adherence to BCR-ABL Inhibitors: Issues for CML Therapy
Treatment for chronic myeloid leukemia (CML) has improved substantially in the last 20 years, especially since the introduction of oral BCR-ABL inhibitors a decade ago. However, for patients to reap the benefits of BCR-ABL inhibitors, they must likely be on therapy for the remainder of their lives....
Salvato in:
| Pubblicato in: | Clin Lymphoma Myeloma Leuk |
|---|---|
| Autori principali: | , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2012
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4428159/ https://ncbi.nlm.nih.gov/pubmed/22633166 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2012.04.002 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|